MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 31, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2022 financial results after
MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 5, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven poster presentations at the 37th Annual Meeting of the
MONROVIA, Calif. --(BUSINESS WIRE)--Sep. 9, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente , M.D., to its board of
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Aug. 3, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported
IRVING, Texas and MONROVIA, Calif. , Aug. 2, 2022 /PRNewswire/ -- Caris Life Sciences ® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, and Xencor , Inc. (NASDAQ: XNCR), a clinical-stage
MONROVIA, Calif. --(BUSINESS WIRE)--Jul. 27, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2022 financial results after
MONROVIA, Calif. --(BUSINESS WIRE)--May 26, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 5, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 28, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release first quarter 2022 financial results
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 8, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from its preclinical-stage
